LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Clinical trial NCT00680901 · COMPLETED
Trial details
- NCT number
- NCT00680901
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2008-06-04
- Primary completion
- 2012-09-24
- Enrollment
- 545
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.